In This Article:
-
Total Revenue: $10.6 million in Q3, down from $16.1 million in Q2.
-
Projected Q4 Revenue: At least $25 million expected.
-
LYFGENIA Revenue: First revenue recognized following initial infusion.
-
Gross to Net Discounts: Anticipated range of 20% to 25% for 2024.
-
SG&A Expense: Consistent with prior-year period.
-
R&D Expense: Down $36.1 million year-over-year.
-
Cash on Hand: $118.7 million as of September 30, 2024, including $48 million in restricted cash.
-
Cash Operating Expenses Reduction: 20% reduction anticipated by Q3 2025.
-
Cash Flow Breakeven: Expected in the second half of 2025 with 40 drug product deliveries per quarter.
Release Date: November 14, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
bluebird bio Inc (NASDAQ:BLUE) more than doubled patient starts from 27 to 57 since the last quarter, indicating strong demand for their therapies.
-
The company has a robust qualified treatment center (QTC) network with over 70 centers, providing broad access to their therapies.
-
bluebird bio Inc (NASDAQ:BLUE) has initiated steps to reduce cash operating expenses by 20% in Q3 2025, aiming for financial stability.
-
The company reported its first LYFGENIA revenue, marking a significant milestone in their commercial operations.
-
There have been zero ultimate denials for their therapies across both Medicaid and commercial payers, indicating strong reimbursement support.
Negative Points
-
Total revenue for the third quarter was $10.6 million, down from $16.1 million in Q2, reflecting variability in manufacturing timelines.
-
The company anticipates a cash gap in the second quarter of 2025, requiring additional financing to extend their runway.
-
There is a need for a reverse stock split to regain compliance with Nasdaq's minimum bid price, indicating potential financial challenges.
-
The cost of goods remains higher than revenue, resulting in negative margins due to high fixed costs associated with manufacturing.
-
bluebird bio Inc (NASDAQ:BLUE) faces variability in patient scheduling and manufacturing timelines, which can impact revenue recognition.
Q & A Highlights
Q: What are the dynamics around the administration of cells after delivery to treatment centers, and is there any dropout from cell manufacturing to administration? A: We still see 100% pull-through once we deliver cells to a patient being treated. There is variability in patient scheduling, but once we deliver the final drug product to the QTC, it's in their hands. We have seen 100% pull-through once delivered.